Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Strata Critical Medical Earnings Call: Key Takeaways

Strata Critical Medical delivered strong Q3 2026 results with record adjusted EBITDA margins and free cash flow, despite seasonal industry headwinds and regulatory-driven shifts in logistics flight distances.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthClinical up 20.3% sequentially; Logistics down 6.9% sequentially due to seasonality.
Mgmt ConfidenceConfident in medium-term 30% plus adjusted EBITDA growth including acquisitions.
Demand VisibilityStrong new customer pipeline for integrated transplant offering in 2027.
Margin TrendsLogistics gross margin rebounded 240bps to 20.8%; Clinical declined 50bps.
Op. LeverageAdjusted SG&A flat over four quarters despite significant organic growth.
Pricing PowerFuel surcharge pass-through revenue impacted logistics margins on owned aircraft.
Vol vs PriceGrowth driven by market share gains despite 7% industry transplant decline.
Segment GrowthClinical growth led by transplant business; Logistics impacted by shorter distances.
New ClientsGaining market share; strong pipeline for integrated transplant offering mentioned.
Capex & DebtFree cash flow $8.6M; $41.6M cash; $50M share buyback authorized.
RegulatoryNew OPTN lung allocation rules reduced average flight distances by 10%.
CommentaryFocusing on 'integrated organ recovery platform' to drive higher cash conversion.
New LaunchesLaunched local recovery business based on customer demand and surgeon retention.

Growth

Revenue grew 20.3% sequentially; Clinical segment organic growth exceeded 30% year-over-year.

Outlook

Reiterated 2026 revenue of $285M-$295M and adjusted EBITDA of $33M-$35M.

Risks

Logistics revenue fell 6.9% sequentially; management pivoted on specific Q4 industry volume recovery timing.

Source

The company's earnings call, NASDAQ: SRTA, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Strata Critical Medical, Inc.: key numbers

Share price
$5.42Close, Nov 16
Market cap
$484M
Shares outstanding
89.32MLatest SEC cover page
Sector
Energy & Transportation
Industry
Transportation ServicesSIC 4700

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Strata Critical Medical, Inc.

All →
12:46 PM ET 10-Q
Financial Results ▶ Call

Strata Critical Medical Q3 2026 Results: Net Loss of $7.62M

Strata Critical Medical, Inc. reported a net loss of $7.6 million for the third quarter of 2026, compared to a net income of $57.4 million in the prior year period, which was significantly bolstered by discontinued operations. Revenue grew to $74.1 million from $49.3 million year-over-year, while the company maintained a cash and cash equivalents balance of $35.1 million as of September 30, 2026.

Key figure
Net loss $7.62M
8:12 AM ET 8-K
Financial Results

Strata Critical Medical Financial Results

Strata Critical Medical reported Q3 2026 financial results with revenue increasing 50.3% year-over-year to $74.1 million, driven by significant growth in its Clinical segment. The company also announced a new $20 million share repurchase authorization to be executed alongside its ongoing M&A strategy.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.